Yes, Pregabalin is a Schedule V Controlled Substance
Pregabalin is classified as a Schedule V controlled substance in the United States, which means it has recognized potential for abuse and dependence, though lower than Schedule I-IV substances 1.
Regulatory Classification
According to the FDA drug label, pregabalin is explicitly designated as a Schedule V controlled substance 1. This classification reflects documented evidence of:
- Abuse potential: In recreational drug users, pregabalin (450 mg single dose) produced subjective ratings of "good drug effect," "high," and "liking" similar to diazepam 30 mg 1
- Euphoria rates: In controlled clinical trials, 4% of pregabalin-treated patients reported euphoria as an adverse reaction, with rates ranging from 1-12% in certain patient populations 1
- Physical dependence: Abrupt discontinuation causes withdrawal symptoms including insomnia, nausea, headache, diarrhea, anxiety, and hyperhidrosis 1
Clinical Context for Your Patient
Given your patient's specific situation (cannot tolerate gabapentin due to drowsiness and has significant alcohol use precluding duloxetine), prescribing pregabalin requires heightened caution due to the documented increased abuse risk in patients with substance use history.
Critical Risk Factors
Patients with alcohol dependence show significantly elevated risk for pregabalin abuse 2, 3. The evidence demonstrates:
- Pregabalin is frequently abused by individuals with prior substance use disorders, particularly for its hypnotic/sedative properties 2, 4
- Co-use with alcohol or other CNS depressants increases risk of dangerous respiratory depression 1
- Higher pregabalin concentrations are found in urine samples when co-detected with other substances of abuse 5
Prescribing Considerations
If you proceed with pregabalin despite these risks:
- Start at the lowest effective dose and monitor closely for signs of misuse (dose escalation, drug-seeking behavior, early refill requests) 1
- Avoid prescribing if the patient is actively drinking, as this combination poses serious respiratory depression risk 1
- Implement prescription monitoring: Check prescription drug monitoring programs (PDMP) regularly
- Taper gradually if discontinuing (minimum 1 week) to minimize withdrawal symptoms 1
Alternative Approach
Consider addressing the alcohol use first before initiating any gabapentinoid, as this fundamentally changes the risk-benefit calculation. Gabapentin itself, while not federally scheduled, may still be preferable despite drowsiness if the sedation can be managed through dose timing (bedtime dosing) or slower titration 6.
Important Caveat
The drowsiness your patient experienced with gabapentin will likely also occur with pregabalin, as somnolence affects 23% of pregabalin-treated patients (vs 8% placebo) 1. Pregabalin is not a solution to gabapentin-related sedation—both are gabapentinoids with similar CNS depressant effects.